Based on deficits in AD,cholinesterase inhibitors (ChEIs) are the first-line drugs in the symptomatic treatmentof AD by inhibiting cholinesterase, and thus resulting in increased synaptic levels ofACh neurotransmitter. This evidence concerns the gene BCHE and Alzheimer disease.